ICON Wins Best Contract Research Organisation at the Annual Scrip Awards 2017
November 30 2017 - 5:34AM
Business Wire
ICON recognised for partnership capabilities
and innovation in patient recruitment
ICON plc, (NASDAQ: ICLR) a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, has won Best Contract
Research Organisation – Full-Service Providers at the 2017 Scrip
Awards, which took place in London on 29 November.
The Scrip Awards honour the pharmaceutical industry’s highest
achieving individuals and organisations, with the Best Contract
Research Organisation acknowledging the critical role that CROs
play in drug development. ICON was selected by a panel of senior
industry experts from around the world, as the best CRO according
to the following criteria:
- Quality of services and relationships
with clients
- Innovations in patient recruitment
strategy
- Capabilities and strengths offered
- Delivery of results that exceed sponsor
expectations
- Improvement in performance
- Progress towards streamlining data
collection and reporting
“We are very proud to be recognised as the industry’s best,”
commented Dr. Steve Cutler, Chief Executive Officer, ICON plc.
“Through innovations in patient recruitment and a strong commitment
to accountability and delivery, we have exceeded customer
expectations in a wide range of studies and have beaten industry
medians in critical study performance metrics. Building
collaborative teams that work in partnership with our customers is
a key focus at ICON and it is very pleasing to see the efforts of
our employees being rewarded.”
ICON continues to drive efficiency in drug development, by
revolutionising the paradigm for site and patient identification,
and improving site relationships, performance and engagement.
Through an owned network of 52 sites and EMR partnerships with IBM
Watson, EHR4CR, and TriNetX, ICON can help sponsors to more easily
identify suitable patients. Furthermore, ICON’s FIRECREST digital
solutions improve the clinical trial experience for sites, patients
and study staff resulting in reduced time, cost and better quality
data.
ICON’s Best CRO Award from Scrip follows a range of other
industry awards throughout 2017, including Best Vaccines CRO,
PharmaTimes Best Partnership in Clinical Research and PharmaTimes
Clinical Researcher of the Year. A full list of ICON’s industry
awards can be viewed at www.iconplc.com/awards.
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 97 locations in 38 countries and has approximately
13,100 employees.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171130005456/en/
ICON Media ContactOlivia PimentaWeber Shandwick+44 (0)207
067 0557OPimenta@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024